|Conţinutul numărului revistei|
|Ultima descărcare din IBN:|
| SM ISO690:2012|
RABA, Tatiana. Tratamentul antiviral cu interferon alfa 2b pegilat şi ribavirină în hepatita cronică virală C la copii în Republica Moldova. In: Sănătate Publică, Economie şi Management în Medicină . 2014, nr. 5(56), pp. 73-76. ISSN 1729-8687.
|Sănătate Publică, Economie şi Management în Medicină|
|Numărul 5(56) / 2014 / ISSN 1729-8687|
The combined antiviral therapy with pegylated interferon alpha 2в and ribavirin is approved in children from 3-year age and teenagers. In compliance with the National Program of the Republic of Moldova in 2007-2011 and 2012-2016 yy 35 children, of age 4-17 years were treated in pediatrics hepatology with pegylated interferon alpha 2в (60 mcg/m2/ week) plus ribavirin (15 mg/kg/day), duration of therapy consisted 24 weeks for genotype 2 or 48 weeks for genotype 1b. Chronic hepatitis C in 35 children was characterized by the minimum clinical signs, low biochemical activity, low virus loading < 600 000 ui/ml in 60% of cases and minimum degree of fibrosis (F0-F2 in 29 of 35 surveyed). 33 patients finished the antiviral treatment, while 2 children discontenued therapy because of the expressed headaches (1) and in connection with immigration overboard of the republic. The received results revealed minimum side effects with achievement of SVR in 73% cases, including: with genotype 1в – 69%, while with genotype 2 and 3а – in 100%. Antiviral therapy in 35 children is seif, but demands an individual approach.
children, genotype, ribavirin,
chronic hepatitis viral C, pegylated interferon, sustained virologic response